Astellas Pharma
Major Japanese pharma company focused on urology, oncology, and transplantation
Company Overview
Peer Companies
Signal Activity
Signal Timeline
2 totalAstellas and Vir Biotechnology Enter Global Strategic Collaboration to Advance Prostate Cancer Treatment VIR-5500
Astellas Pharma and Vir Biotechnology have initiated a global strategic collaboration to co-develop and co-commercialize VIR-5500, a novel T-cell engager for treating prostate cancer. Vir Biotechnology will receive $335 million in initial payments. The partnership will share development costs, with Astellas leading future development and global commercialization. Vir Biotechnology retains co-promotion rights in the United States. This collaboration aims to accelerate the development of VIR-5500, which is currently in Phase I trials.
Astellas Pharma's Veoza Recommended by UK's NICE for NHS Use in Treating Menopause-Related Hot Flushes
The UK's National Institute for Health and Care Excellence (NICE) has recommended Astellas Pharma's drug, Veoza, for use within the National Health Service (NHS). This recommendation is for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause. The decision makes Veoza an accessible option for women in the UK experiencing these symptoms, following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
Get notified when new signals are published for this company.